Antibody to programmed death-ligand 1 (PD-L1) and use thereof
Inventors
Park, Jae Eun • Choi, Soo A • LEE, Jisu • Lee, Hyun Mi • LEE, Si Hyung • Baek, Gi Sun • KIM, Yeung Chul • Park, Bum-Chan • Lim, Jung Chae • Cho, Young-Gyu • Park, Young Woo
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10919966-B2
Publication Date
2021-02-16
Expiration Date
Abstract
Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.
Core Innovation
The disclosure describes an antibody binding to PD-L1 or an antigen-binding fragment thereof. The antibody is defined by specific heavy chain CDR1, CDR2, and CDR3 combinations and specific light chain CDR1, CDR2, and CDR3 combinations using SEQ ID NO sets. Multiple CDR pairings are provided, each comprising a particular heavy chain CDR1/2/3 and a particular light chain CDR1/2/3 combination.
The disclosed antibodies are intended to block PD-1/PD-L1 complex formation to prevent T-cell depletion. In this context, PD-L1 binding by the antibody or antigen-binding fragment is presented as functionally important for counteracting the PD-1/PD-L1 pathway. The disclosure also provides antibodies and antigen-binding fragments that can include framework region selections and sequence-identity constraints as part of the defined constructs.
The disclosure further supports the antibodies with nucleic acids, vectors, transformed host cells, and production by culturing and recovery. Supporting experimental work in the disclosure includes PD-L1 antigen expression/purification, identification of PD-L1 binders by phage-display screening, conversion to IgG, and functional blockade assessment of PD-1/PD-L1 complex formation.
Claims Coverage
The document contains one independent claim directed to PD-L1-binding antibodies (or antigen-binding fragments) defined by multiple specified heavy- and light-chain CDR combinations. The independent claim is further refined by dependent claims that add framework region sequence selections, nucleic acid/construct scope, and therapeutic composition and production aspects.
PD-L1-binding antibody defined by specified heavy- and light-chain CDR combinations
An antibody binding to PD-L1 or an antigen-binding fragment thereof, comprising a heavy chain variable region comprising specified heavy chain CDR1, CDR2, and CDR3 using the cited SEQ ID NOs, and a light chain variable region comprising specified light chain CDR1, CDR2, and CDR3 using the cited SEQ ID NOs, where the claim includes multiple alternative CDR combination sets.
Overall claim coverage centers on a PD-L1-binding antibody (or antigen-binding fragment) whose scope is determined by the particular heavy-chain and light-chain CDR1/2/3 assignments to specified SEQ ID NOs, with dependent claims narrowing framework selections, adding nucleic acid and production-related elements, and specifying composition contexts.
Stated Advantages
Blocks PD-1/PD-L1 complex formation to prevent T-cell depletion.
Documented Applications
Therapeutic compositions for preventing or treating cancer in which the active ingredient is an antibody or an antigen-binding fragment thereof that binds PD-L1.
Therapeutic compositions for preventing or treating infectious diseases in which the active ingredient is an antibody or an antigen-binding fragment thereof that binds PD-L1.
Interested in licensing this patent?